✦ LIBER ✦

Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

✍ Scribed by Andre, F.; Bachelot, T.; Campone, M.; Dalenc, F.; Perez-Garcia, J. M.; Hurvitz, S. A.; Turner, N.; Rugo, H.; Smith, J. W.; Deudon, S.; Shi, M.; Zhang, Y.; Kay, A.; Graus Porta, D.; Yovine, A.; Baselga, J.

Book ID: 125332028
Publisher: American Association for Cancer Research
Year: 2013
Tongue: English
Weight: 482 KB
Volume: 19
Category: Article
ISSN: 1078-0432
DOI: 10.1158/1078-0432.CCR-13-0190

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Disposition and metabolism of14C-dovitin

Disposition and metabolism of14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors

✍ Anne-Charlotte Dubbelman, Alana Upthagrove… 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 735 KB

Radiosensitizers in pancreatic cancer—Pr

Radiosensitizers in pancreatic cancer—Preclinical and clinical exploits with molecularly targeted agents

✍ Walker, Amanda J.; Alcorn, Sara R.; Narang, Amol K.; Nugent, Katriana M.; Wild, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 312 KB

Molecular Pathways: Preclinical Models a

Molecular Pathways: Preclinical Models and Clinical Trials with Metformin in Breast Cancer

✍ Thompson, A. M. 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 599 KB

Clinical pharmacology of tamoxifen in pa

Clinical pharmacology of tamoxifen in patients with breast cancer: Correlation with clinical data

✍ Carol Fabian; Larry Sternson; Moustafa El-serafi; Lyn Cain; Erwin Hearne 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 643 KB

A multicenter, nonrandomized, open-label

A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer

✍ G. Konecny; N. Finkler; P. Lee; A. Yovine; A. Liu; P. Sen; M. Squires; A. Kay 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Preclinical and clinical studies of estr

Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

✍ Marion T Weigel, Zara Ghazoui, Anita Dunbier, Sunil Pancholi, Mitch Dowsett, Les 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 710 KB